Results 31 to 40 of about 2,206,632 (403)

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

New England Journal of Medicine, 2021
Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
J. Sadoff, Mathieu le Gars, Georgi Shukarev, Dirk Heerwegh, C. Truyers, A. M. de Groot, Jeroen N. Stoop, Sarah M. Tete, W. Van Damme, I. Leroux-Roels, Pieter-Jan Berghmans, M. Kimmel, P. van Damme, J. D. de Hoon, William Smith, K. Stephenson, Stephen C. De Rosa, Kristen W. Cohen, M. McElrath, E. Cormier, Gert Scheper, D. Barouch, J. Hendriks, F. Struyf, M. Douoguih, J. van Hoof, H. Schuitemaker   +26 more
semanticscholar   +1 more source

Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

Human Vaccines & Immunotherapeutics, 2017
A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a ...
Christopher A. Seid, Kathryn M. Jones, Jeroen Pollet, Brian Keegan, Elissa Hudspeth, Molly Hammond, Junfei Wei, C. Patrick McAtee, Leroy Versteeg, Amanda Gutierrez, Zhuyun Liu, Bin Zhan, Jonathan L. Respress, Ulrich Strych, Maria Elena Bottazzi, Peter J. Hotez   +15 more
doaj   +1 more source

Development of an inactivated vaccine candidate for SARS-CoV-2

Science, 2020
Vaccine candidate tested in monkeys Global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent race to develop a vaccine. Gao et al.
Q. Gao, L. Bao, H. Mao, Lin Wang, K. Xu, Minnan Yang, Yajing Li, Ling Zhu, Nan Wang, Zhe Lv, Hong Gao, Xiaoqin Ge, B. Kan, Yalin Hu, Jiangning Liu, Fang Cai, D. Jiang, Yanhui Yin, C. Qin, Jing Li, X. Gong, X. Lou, W. Shi, Dongdong Wu, Hengming Zhang, Lang Zhu, Wei Deng, Yurong Li, Jinxing Lu, Changgui Li, Xiangxi Wang, W. Yin, Yanjun Zhang, Chuan Qin   +33 more
semanticscholar   +1 more source

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

New England Journal of Medicine, 2021
Background Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making.
A. Jara, E. Undurraga, Cecilia González, F. Paredes, Tomás Fontecilla, G. Jara, A. Pizarro, Johanna Acevedo, Katherine Leo, Francisco Leon, Carlos Sans, Paulina Leighton, P. Suárez, Heriberto E. García-Escorza, R. Araos   +14 more
semanticscholar   +1 more source

SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice

Human Vaccines & Immunotherapeutics, 2021
There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low- and middle-income countries. Here, we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast (Pichia ...
Jeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, Brian Keegan, Bin Zhan, Junfei Wei, Zhuyun Liu, Jungsoon Lee, Rahki Kundu, Rakesh Adhikari, Cristina Poveda, Maria Jose Villar, Ana Carolina de Araujo Leao, Joanne Altieri Rivera, Zoha Momin, Portia M. Gillespie, Jason T. Kimata, Ulrich Strych, Peter J. Hotez, Maria Elena Bottazzi   +19 more
doaj   +1 more source

Knowledge About the Human Papillomavirus Vaccine Among Employees at a Tertiary Cancer Center: Room for Improvement [PDF]

, 2020
Introduction: The human papillomavirus (HPV) vaccine is recommended by the U.S. Centers for Disease Control and Prevention for routine vaccination of boys and girls to protect against HPV-related cancers and genital warts. To meet the Healthy People 2020
Baum, George P, Bello, Rosalind S, Dahlstrom, Kristina R, DePinho, Ronald A, Hawk, Ernest, Ramondetta, Lois M, Stevens, Lori D, Sturgis, Erich M, Tamez, Elenita   +8 more
core   +2 more sources

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

New England Journal of Medicine, 2021
Background On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least ...
Y. Bar-On, Y. Goldberg, Michael I. Mandel, O. Bodenheimer, L. Freedman, N. Kalkstein, B. Mizrahi, S. alroy-Preis, N. Ash, R. Milo, A. Huppert   +10 more
semanticscholar   +1 more source

Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction [PDF]

, 2018
PURPOSE: The aims of this study were to determine prevalence of and factors associated with any human papillomavirus (HPV) and vaccine-type HPV among young men after vaccine introduction, stratified by vaccination status.
Bernstein, David I., Brown, Darron A., Chandler, Emmanuel, Ding, Lili, Franco, Eduardo L., Gorbach, Pamina, Kahn, Jessica A., Widdice, Lea E.   +7 more
core   +1 more source

Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction [PDF]

, 2019
Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine introduction is essential to guide vaccination recommendations and policies.
Bernstein, David I., Brown, Darron, Covert, Courtney, Ding, Lili, Franco, Eduardo L., Kahn, Jessica A.   +5 more
core   +1 more source

Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021

Nature Communications, 2022
The COVID-19 pandemic continues to impact daily life, including health system operations, despite the availability of vaccines that are effective in greatly reducing the risks of death and severe disease.
J. Lazarus, K. Wyka, Trenton M. White, C. Picchio, Kenneth H. Rabin, S. Ratzan, J. Parsons Leigh, Jia Hu, A. El-Mohandes   +8 more
semanticscholar   +1 more source